Incorporated in 2002, Bowsher Brunelle Smith LLC (d/b/a B2S Consulting®) was an Indianapolis-based firm offering a range of consulting services to support R&D of biotherapeutics and conventional pharmaceuticals. Leveraging their decades of combined experience in drug development and applied statistics, Dr. Bowsher and his business partners offered cutting-edge and in-depth support for nonclinical and clinical drug development, including:

  • Regulated bioanalysis and ligand binding assays
  • Clinical trial statistics and outcomes research
  • Support for proteins, peptides and biosimilars
  • Immunogenicity testing including statistical support for screening and confirmatory cut points
  • Immune safety testing and immunotoxicology
  • CMC support and protein formulation
  • Clinical drug development and ADME
  • Regulatory sciences and quality compliance

In January 2017, these core competencies were consolidated under the network of B2S Life Sciences®, a service-driven Biotherapeutic Enablement Company™ offering premier laboratory analysis and life cycle management of custom reagents. The consequent growth culture catalyzed by this integration strategy significantly augments the espoused values and vision of B2S Consulting® originated in 2002, and sets the stage for biological innovation. Today, B2S Life Sciences® serves pharma and biotechnology clients by offering a wide range of Pre-Analytical (generation of custom reagents) and Post-Analytical (data analytics and statistics, pharmacokinetic data analysis, and clinical immunogenicity) services.

B2S Life Sciences